Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print   

Thursday 24 June, 2021

Oxford Biomedica PLC

Directors Dealings / Market Share Purchases

RNS Number : 0372D
Oxford Biomedica PLC
24 June 2021
 

 

 

Directors Dealings / Market Share Purchases

 

Oxford, UK - 24 June 2021:   Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces   that two of the Company's Non-Executive Directors have purchased shares in the Company.  

 

As stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to £50,000 per annum may be paid to any Non-Executive Director recruited from or based in the United States to reflect market levels of remuneration in the United States for Non-Executive Directors, subject to their agreement that the after tax amount of this additional fee will be applied in the acquisition of Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition.

 

Dr. Heather Preston, Non-Executive Director of the Group, has purchased 2,235 ordinary shares of 50p each ("Ordinary Shares") in the Company on 23 June 2021 on the London Stock Exchange at a price of 1288p under the terms of a market purchase agreement. Following this purchase Dr. Heather Preston holds 2,235 Ordinary Shares representing 0.003% of the Company.

 

Dr. Siyamak Rasty, Non-Executive Director of the Group, has purchased 2,235 Ordinary Shares in the Company on 23 June 2021 on the London Stock Exchange at a price of 1288p under the terms of a market purchase agreement. Following this purchase Dr. Siyamak Rasty holds 2,235 Ordinary Shares representing 0.003% of the Company.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares purchased.

 

 1.

Details of the person discharging material responsibilities/person closely   associated

 

 a.

Name

 Heather Preston

 

 2.

Reason for the notification

 

 a.

Position/status

 Non-Executive Director

 b.

Initial notification /amendment

 Initial notification

 

3.

Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor

 

 a.

Name

 Oxford Biomedica plc

 

 b.

Legal Entity Identifier

 213800S1GVQNXQ15K851

 

4.

Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 a.

Description of the financial instrument, type of instrument identification code

 Oxford Biomedica plc Ordinary Shares of 50p each

 

 

 GB00BDFBVT43

 

b.

Nature of the transaction

 Purchase of ordinary shares

 

c.

Currency

 GBP - British Pound

 

d.

Price(s) and volume(s)

 

Price(s)

 

 

Volume(s)

£12.88

2,235

 

 

 

 

e.

Aggregated information

· Aggregated volume

· Price

· Aggregated total

 

 

 2,235

 

 12.88

 28,786.80

 

f.

Date of the transaction

 2021-06-23

 

g.

Place of the transaction

 London Stock Exchange, Main Market (XLON)

 

 

 

 1.

Details of the person discharging material responsibilities/person closely   associated

 

 a.

Name

 Siyamak Rasty

 

 2.

Reason for the notification

 

 a.

Position/status

 Non-Executive Director

 b.

Initial notification /amendment

 Initial notification

 

3.

Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor

 

 a.

Name

 Oxford Biomedica plc

 

 b.

Legal Entity Identifier

 213800S1GVQNXQ15K851

 

4.

Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 a.

Description of the financial instrument, type of instrument identification code

 Oxford Biomedica plc Ordinary Shares of 50p each

 

 

 GB00BDFBVT43

 

b.

Nature of the transaction

 Purchase of ordinary shares

 

c.

Currency

 GBP - British Pound

 

d.

Price(s) and volume(s)

 

Price(s)

 

 

Volume(s)

£12.88

2,235

 

 

 

 

e.

Aggregated information

· Aggregated volume

· Price

· Aggregated total

 

 

 2,235

 

 12.88

 28,786.80

 

f.

Date of the transaction

 2021-06-23

 

g.

Place of the transaction

 London Stock Exchange, Main Market (XLON)

 

 

 

The issued share capital of the Group is 82,591,804 Ordinary Shares.

 

 

-Ends-

 

For further information, please contact:

 

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEAFFLEFSEDM

a d v e r t i s e m e n t